1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aprogen Biologics Inc.

Aprogen Biologics Inc.

003060.KS
Aprogen Biologics Inc.KR flagKorea Exchange
2,085.00
KRW
+85.00
- -
27.48BMarket Cap
Aprogen Biologics Inc.
003060.KS
(Korea Exchange)

Recent

price

2,085.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
48,785.51
116,210.44
47,841.42
36,521.99
36,356.85
38,989.43
41,228.35
43,184.12
34,181.96
31,335.63
18,895.06
15,884.32
18,216.86
157,801.75
8,034.85
5,555.91
5,918.78
Revenue per Share
-2,059.17
-10,572.66
-35,234.63
-25,777.7
-4,270.86
2,669.29
-3,660.74
-15,329.34
-915.19
-5,118.37
3,987.69
2,278.68
3,531.96
-213,626.31
-12,518.74
-12,923.54
-9,956.43
Basic EPS, GAAP
-35,639.18
-19,733.34
-3,897.73
-14,096.91
-10,011.26
-5,499.39
-2,214.84
-10,844.45
-687.42
-1,051
2,362.47
-2,156.66
6,757.72
-112,072.79
-5,538.96
-3,642.85
-3,184.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
36,528.84
47,240.06
42,971.14
27,653.79
30,271.9
32,810.85
27,638.65
12,951.86
15,554.67
48,666.8
59,950.3
50,107.52
79,582.52
360,471.35
-16,694.4
-23,526.49
-23,876.53
Book Value per Share
114,310.59
159,451.79
90,382.42
67,464.93
65,864.09
61,512.94
68,423.77
68,702.44
110,854.47
211,840.1
210,751.89
167,158.39
140,825.02
654,681.43
44,548.83
20,659.55
20,328.53
Tangible Book Value per Share
- -
- -
1
1
1
1
1
1
1
2
3
4
4
1
8
13
13
Basic Weighted Avg Shares
16,689
50,123
33,770
29,543
33,092
40,324
44,122
46,101
45,395
50,904
53,320
56,482
65,190
87,364
67,378
73,226
77,998
Sales/Revenue/Turnover
7.6
0.92
-48.54
-45.87
-16.17
-2.15
-0.56
-3.16
-1.82
-3.79
-1.82
-6.97
-5.33
-66.15
-79.13
-82.6
-74.68
Operating Margin (%)
410
970
948
790
1,387
1,599
1,428
1,675
1,466
1,661
1,932
2,072
2,404
21,398
19,090
19,185
19,077
Depreciation Expense
-704
-4,560
-24,871
-20,852
-3,887
2,761
-3,918
-16,365
-1,215
-8,315
11,253
8,103
12,639
-118,270
-104,979
-170,331
-131,207
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.91
8.47
- -
- -
- -
- -
Effective Tax Rate (%)
-4.22
-9.1
-73.65
-70.58
-11.75
6.85
-8.88
-35.5
-2.68
-16.33
21.1
14.35
19.39
-135.38
-155.81
-232.61
-168.22
Profit Margin (%)
17,349
30,906
46,009
33,860
38,183
39,252
37,919
32,038
25,244
202,731
327,848
344,025
79,502
-73,081
-32,308
-74,604
-74,696
Working Capital
5,370
4,033
2,294
8,332
8,395
4,139
1,080
24,894
- -
228
164
120
129
50,277
48,197
58,675
52,878
LT Debt
42,807
73,488
68,508
56,547
62,113
67,745
78,120
76,814
150,511
347,637
598,356
597,181
510,411
368,691
378,691
277,567
272,847
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.61
-0.51
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.65
3.08
- -
- -
- -
- -
Return on Capital (%)
- -
-27.75
-98.1
-79.13
-15.57
8.98
-12.34
-75.4
-7.05
-16.68
9.07
4.67
5.46
-48.84
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
152,174
170,121
174,277
LT Borrowings
40,000
40,000
38,000
LT Finance Leases
- -
18,675
14,878
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
121,112
102,540
58,284

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
181,009
154,529
151,945
Cash, Cash Equivalents & STI
47,569
51,633
50,102
Accounts Receivable, Net
14,369
15,663
14,814
Inventories
53,119
51,601
56,150
Total Current Liabilities
211,437
229,133
226,640
Payables & Accruals
- -
- -
- -
ST Debt
152,174
170,121
174,277
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.62%
-13.3%
-26.7%
Free Cash Flow
-117.42%
-201.74%
3.37%
Net Income, GAAP
-62.47%
-191.35%
62.25%
Sales/Revenue/Turnover
7.04%
8.23%
8.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,606
15,192
14,531
22,049
67,378
2025
16,848
14,896
21,118
20,364
73,226
2026
21,620
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-69.15
-5,187.41
-1,364.32
- -
-12,518.74
2025
-3,264.17
-5,075.94
-1,849.66
- -
-12,923.54
2026
-295.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Societal CDMO, Inc. (SCTL)
Hainan Poly Pharm. Co., Ltd (300630.SZ)
Cohance Lifesciences Limited (COHANCE.NS)
Hypera S.A. (HYPE3.SA)
Indivior PLC (INVVY)
Orchid Ventures, Inc. (ORVRF)
Business
Aprogen Biologics Inc. (003060.KS) manufactures and sells pharmaceutical and biopharmaceutical products in South Korea. The company produces synthetic pharmaceuticals including circulatory system drugs, central nervous system drugs, digestive system drugs, antibiotics, anti-biotic, anti-fungal, anti-viral, and anti-ulcerant products; biopharmaceuticals such as biosimilars, recombinant proteins, and novel biologics including biosimilar versions of Remicade, Herceptin, and Rituxan, alongside pipelines like AP102 and AP202 for blood vessel diseases and tumors; external agents, anti-cancer drugs, amino-acid nutrient transfusion agents, anti-allergy medications, osteoarthritis treatments, skeletal muscle relaxants, NSAIDs, osteoporosis drugs, endocrine products, and cosmetics. Founded in 1960 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, with additional facilities in Cheongju-si, Chungcheongbuk-do, Aprogen Biologics operates primarily in the domestic market through its pharmaceutical and bio business divisions, serving healthcare providers and patients with over 200 medical products. In recent developments, the company received KRW 15 billion in funding from APTN Inc. in October 2025; completed production of clinical drug materials for a new degenerative arthritis treatment in September 2025 using its biopharmaceutical facilities; and underwent a corporate restructuring in December 2022 when Aprogen Pharmaceuticals Inc. acquired Aprogen Biologics from Aprogen Inc., alongside a 6.87% stake sale to an undisclosed buyer in July 2024 for KRW 43.9 billion.